TMC114-TiDP3-C176 - A Study in Healthy Volunteers Investigating the Bioequivalence Between Two Commercially Available 400-mg Tablets to One New 800-mg Tablet of Darunavir (DRV) in the Presence of Low-dose Ritonavir Under Fed and Fasted Conditions

NCT01308658 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
128
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Tibotec Pharmaceuticals, Ireland